{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/combining-multiple-therapies-metastatic-breast-cancer-adcs-and-icis#webpage",
"url": "https://www.fortrea.com/insights/combining-multiple-therapies-metastatic-breast-cancer-adcs-and-icis",
"name": "Combining multiple therapies for metastatic breast cancer ADCs and ICIs",
"description": "This Fortrea white paper explores metastatic breast cancer research and the evolving treatment strategies involving antibody-drug conjugates and immune checkpoint inhibitors across oncology research environments. The content focuses on metastatic breast cancer research, ADC therapies, immune checkpoint inhibitors, evolving treatment strategies, and therapeutic approaches affecting metastatic breast cancer studies. The white paper highlights considerations related to combination therapy research, treatment response variability, emerging oncology approaches, and scientific perspectives associated with metastatic breast cancer clinical development. Fortrea discusses oncology research perspectives designed to support understanding of ADC and immune checkpoint inhibitor treatment strategies and their role within metastatic breast cancer research programs. By integrating scientific understanding of antibody-drug conjugates with immune checkpoint inhibitor approaches and evolving oncology treatment considerations, the white paper provides insights into metastatic breast cancer research and advancing therapeutic strategies across oncology clinical development environments."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Combining multiple therapies for metastatic breast cancer ADCs and ICIs",
"item": "https://www.fortrea.com/insights/combining-multiple-therapies-metastatic-breast-cancer-adcs-and-icis"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/combining-multiple-therapies-metastatic-breast-cancer-adcs-and-icis#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/combining-multiple-therapies-metastatic-breast-cancer-adcs-and-icis#webpage"
},
"headline": "Evolving Treatment Strategies for Metastatic Breast Cancer Using ADCs and ICIs | Fortrea White Paper",
"description": "This Fortrea white paper explores metastatic breast cancer research and the evolving treatment strategies involving antibody-drug conjugates and immune checkpoint inhibitors across oncology research environments. The content focuses on metastatic breast cancer research, ADC therapies, immune checkpoint inhibitors, evolving treatment strategies, and therapeutic approaches affecting metastatic breast cancer studies. The white paper highlights considerations related to combination therapy research, treatment response variability, emerging oncology approaches, and scientific perspectives associated with metastatic breast cancer clinical development. Fortrea discusses oncology research perspectives designed to support understanding of ADC and immune checkpoint inhibitor treatment strategies and their role within metastatic breast cancer research programs. By integrating scientific understanding of antibody-drug conjugates with immune checkpoint inhibitor approaches and evolving oncology treatment considerations, the white paper provides insights into metastatic breast cancer research and advancing therapeutic strategies across oncology clinical development environments.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-03/metastatic-breast-cancer-adc-and-icis.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-03-17",
"dateModified": "2025-03-17",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-03/metastatic-breast-cancer-adc-and-icis.pdf",
"encodingFormat": "application/pdf"
}
}
]
}